Outdated criteria for drug plan reimbursement obstruct evidence based care


12 October 2021 - An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the findings of 2 articles related to the clinical value of direct oral anticoagulants, published this week in CMAJ.

Kimpton and colleagues found that apixaban was both more effective and less expensive than the alternatives when used for primary venous thromboprophylaxis in patients with cancer.

Read CMAJ Editorial

Michael Wonder

Posted by:

Michael Wonder